The firm is a venture capital firm with offices in Western Europe. The firm makes equity investments in early- to late-stage therapeutics, diagnostics, and medical device companies, typically allocating between €2 million and €10 million per investment. The firm invests exclusively in companies based in Central and Western Europe and is actively seeking new opportunities.
The firm is highly opportunistic within the life sciences sector, focusing on therapeutics, diagnostics, and medical devices while also maintaining interest in digital health. In therapeutics, the firm targets products that are in clinical trials or ready to enter Phase I. In medical devices, the firm seeks technologies that are CE Mark ready. While open across subsectors and indications, the firm does not invest in cosmetics or dental devices. The firm strongly favors companies developing products that address significant unmet medical needs.
In digital health, the firm prefers products that either have or are pursuing regulatory approval to monitor or treat medical conditions with unmet needs, typically incorporating both hardware and software components. The firm does not invest in consumer or lifestyle health products. The firm’s prior investments include companies developing small molecule therapeutics for women’s health and diagnostics targeting autoimmune, allergic, ophthalmic, inflammatory, and liver diseases, as well as a medical device company treating prostate cancer.
The firm typically acts as a lead or co-lead investor in most financing rounds and requires a board seat in its portfolio companies. The firm seeks to partner with companies that have strong and experienced management teams.
If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.
Next Phase Newsletter 
Leave a comment